TABLE 4.
apoC-III in VLDL and HDL during the atorvastatin or placebo run-in period and following addition of anacetrapib
| Panel A (N = 26) | Panel B (N = 9) | All Subjects (N = 35) | ||||||||||
| Period 1 (ATV) | Period 2 (ANA+ATV) | Percent Change from Period 1 (95% CI) | P | Period 1 (PBO) | Period 2 (ANA) | Percent Change from Period 1 (95% CI) | P | Period 1 | Period 2 | Percent Change from Period 1 (95% CI) | P | |
| apoC-III in VLDLa (μg/ml) | 37.80 (27.60) | 16.00 (23.20) | −51.49 (−66.16, −31.09) | <.001 | 39.60 (40.80) | 12.00 (6.40) | −70.77 (−90.59, −25.19) | 0.020 | 39.60 (29.20) | 14.00 (22.80) | −56.00 (−69.15, −40.56) | <0.001 |
| apoC-III in HDLb (μg/ml) | 79.59 (49.35) | 97.50 (32.01) | 22.50 (4.31, 43.86) | 0.015 | 72.48 (71.33) | 107.73 (33.65) | 48.64 (11.95, 97.35) | 0.008 | 75.95 (54.08) | 102.49 (32.24) | 34.94 (14.65, 58.82) | <0.001 |
a
Nonparametric method used. Median (IQR) on raw scale displayed under period 1 and period 2. Hodges-Lehmann estimate (95% CI) back transformed from log scale displayed under percent change from period 1. P value from Wilcoxon signed rank test. ATV, atorvastatin; ANA, anacetrapib; PBO, placebo.
b
Mixed model analysis performed on log scale. Geometric mean (% CV) displayed under period 1 and period 2. Percent change from period 1 and corresponding 95% CI calculated using 100 × (GMR − 1); (panel A, N = 28; panel B, N = 9; all subjects, N = 37).